Ron Zwanziger, CEO of LumiraDx, a point of care diagnostic company, said that health care is looking to change from a centralized hospital setting to a community setting, according to a press release.
The LumiraDx D-Dimer test is at present available throughout Europe. The commercialization of LumiraDx NT-proBNP test is expected to start later in 2022.
"The new and updated CE Marks for our NT-proBNP and D-Dimer tests represent an important advancement in cardiovascular testing in the point of care space," Zwanziger said in a press release. "Health care systems in Europe and globally are looking to shift care from centralized hospital settings to community settings."
He also touted the speed of the tests.
"Our new tests deliver results in minutes from an easy-to-collect fingerstick sample, allowing fast and accurate management of cardiovascular conditions by first responders, primary care, urgent care and the emergency department," Zwanziger said in a press release. "Being able to do this at the point of care can improve patient pathways, reduce strains on health systems, specifically emergency departments and lead to improved patient outcomes."
The two tests can complete their results in either 12 or six minutes and are believed to be very portable, according to a press release.